GTX, Jakks Pacific, Hub International, more

MichaelBaron

Advancers

Abraxis BioScience
ABBI
shares rose 4% after the company reported fourth-quarter adjusted earnings of $46.7 million, or 29 cents a share, up from a year-ago equivalent profit of $14.8 million, or 9 cents a share. Revenue rose in the latest three months to $257.1 million from $145.6 million in the same period a year earlier.

Dow Chemical
DOW, +1.08%
shares surged 3.5% following a report from a British tabloid that the company may receive a leveraged buyout offer from a consortium of private equity firms worth up to $54 billion. See full story.

GulfMark Offshore Inc.
GMRK
shares gained 5.7% after the company said its fourth-quarter net income jumped to $30.6 million, or $1.42 a share, from $8.2 million, or 39 cents a share, a year earlier. The firm, which provides marine transportation for the oil and gas industry, said revenue for the quarter rose 34% to $69 million, largely due to higher rates and the addition of new vessels. The firm said profit also benefited by around 17 cents a share from a previously announced sale. Analysts polled by Thomson Financial had been expecting earnings of 90 cents a share on revenue of $62 million. The company also said it expects demand for vessel services to remain strong throughout all of its markets in 2007.

Hub International Ltd.
HBG, +0.31%
shares jumped 15% after the company agreed to be acquired private-equity firm Apax Partners and Morgan Stanley Principal Investments in a deal valued at roughly $1.8 billion. See full story.

Jakks Pacific Inc.
JAKK, +0.00%
shares leapt 17% after the company said its fourth-quarter net income rose to $23.2 million, or 73 cents a share, from $9.0 million, or 30 cents a share, a year ago. On an adjusted basis, net income totaled 84 cents a share. Analysts had been expecting the designer and marketer of toys to report earnings of 67 cents a share, according to data compiled by Thomson Financial. Sales rose to $238.3 million, from $166.3 million last year. The company said that it's expecting 2007 sales to reach at least $800 million, with net income of $75.8 million, or $2.39 a share. First quarter net sales are forecast in a range of $114 million to $120 million, while earnings are expected in a range of 7 to 10 cents a share.

GTX Inc.
GTXI, +1.69%
shares surged 8.8% after analysts at Lazard Research maintained their buy rating on the company, citing the company's recent release of positive data for its treatment Acapodene, a treatment for negative side effects associated with a leading prostate cancer therapy called ADT. The analysts also raised their price target for the stock to $25 from $21.

Mace Security International Inc.
MACE, +4.41%
shares rose after the company said it has rejected a $3-per-share indication of interest from Kelly Capital. Mount Laurel, N.J.-based Mace, a maker of electronic surveillance and personal defense products, also said that it has decided to enter into talks with Kelly Capital regarding the possibility of Kelly paying more than $3 per share. Kelly Capital has signed a confidentiality agreement with Mace and is currently conducting due diligence, Mace said.

Temple-Inland
TIN, +0.00%
shares jumped 13% after the company moved to spin off its financial-services and real-estate units and sell a portion of its timberland holdings to concentrate on packaging and building products. See full story.

TXU Corp.
TXU
shares gained 13% after the company said its board has agreed to a deal to be taken private by an investor group led by Kohlberg Kravis Roberts, Texas Pacific Group and Goldman Sachs. See full story.

Decliners

Shares of Arris Group
ARRS, +0.12%
tumbled 9% Monday after the company's bid to acquire Norway's Tandberg Television was trumped by Ericsson
ERIC, +0.00%
which made a SEK9.8 billion ($1.4 billion) cash offer Tandberg in an effort to position itself to capitalize on the rise of demand for television over the Internet. See full story.

Shares of Cytori Therapeutics
CYTX, +5.46%
slid 6.5% after the company said it's raised roughly $21.5 million through a direct stock offering. The San Diego-based biotechnology company said it's agreed to sell 3.75 million common shares for $5.74 per share. The deal also includes five-year warrants covering the purchase of up to an additional 1.87 million common shares for $6.25 each. Cytori plans to use the funds for clinical trials of its Celution Systems for cardiovascular disease and breast reconstruction post lumpectomy as well as general working capital and other purposes.

Instituform Technologies
INSU
shares fell 8.9% after the company was downgraded to hold from buy at Stifel Nicolaus.

Moody's Corp.
MCO, +0.92%
shares slipped 3.1% after the company was downgraded to underperform from neutral at Credit Suisse. The firm also lowered its price target on the stock to $64 from $79, citing concerns about fallout from weakness in the subprime mortgage market.

Novartis
NVS, -0.36%
shares dipped 2.6% after the Food and Drug Administration said it wants the company to conduct another study about a key diabetes drug. The company said the FDA is seeking further study of Galvus, designed to treat Type 2 diabetes, in specific patient groups with kidney problems. See full story.

Intraday Data provided by SIX Financial Information and subject to terms of use. Historical and current end-of-day data provided by SIX Financial Information. All quotes are in local exchange time. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements.